Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Do Negative Trials Count More Than Successful Ones?

This article was originally published in The Pink Sheet Daily

Executive Summary

Fabre-Kramer, FDA dispute over efficacy of the antidepressant gepirone heads to Psychopharmacologic Drugs Advisory Committee.


Related Content

Will Alkermes Data Package Support ALKS 5461 Approval?
FDA Ruling On Gepirone Efficacy Data Delayed By One Month
Defining 'Substantial Efficacy': Post Hoc Analysis OK (When FDA Does It)
Fabre-Kramer's Gepirone: Lots Of Studies, Not Enough Efficacy
Is Fabre-Kramer’s Gepirone Antidepressant Rising From The Dead After 8 Years?
Third Strike For Gepirone ER: Fabre-Kramer/GSK Antidepressant “Not Approvable” Again


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst